immuno-oncology innovation forum, May 24-25, 2022, by Sachs Associates

When: May 24-25, 2022

FreeMind is proud to partner with Sachs Associates and to support the 8th annual Immuno-Oncology Innovation Forum. Get 10% off as a member of the FreeMind community.

Following the success of last year’s event, we are pleased to announce, our 8th Annual Immuno-Oncology Innovation Forum (#Sachs_IOIF) which will take place virtually on the 24th-25th of May 2022.

Due to the pandemic, the #Sachs_IOIF event will be once again hosted in a digital format. This will allow us to further support our community and past attendees, bridging Europe and the US. We will provide both the usual stimulating program and networking opportunities through our online video and audio meeting system.

The programme for the 8th Annual IOIF will be spread throughout 2 days. Featuring more than 12 hours of keynotes, high-level speeches, panel discussions and spotlight showcases by leading corporates. The event brings together leaders from cancer research institutes, patient advocacy groups, early and late-stage investors, pharma’s and biotech’s.

We anticipate over 300 delegates and 20+ company presentations by established listed, private and emerging companies. Over half of these attendees are corporate and financial investors, analysts, bankers and advisors.

The forum is highly transactional and based on past events we anticipate a high level of activity on the Online Meeting System, which will be open the whole week of the conference, from 23rd to 27th of May.   The conference will be held in the Eastern Daylight Time (EDT) zone and will consist of:

Tuesday, 24th of May:

  • Industry Roundtable
  • Big Pharma Strategy and M&A Panel
  • Business Development Strategies: Creating Value in Times of Limited Resources Panel
  • Investor Panel
  • Early-Stage Innovation Panel

Wednesday, 25th of May:

  • China Partnering & Investment Panel
  • Cell Therapy Evolution & Revolution: Paradigm Shifting Platforms Panel
  • Cancer Vaccines, Neo Antigens & Related Modalities Panel
  • Optimizing the Inherent Combination Value of Oncolytic Viruses Panel

Online Virtual Meetings (23rd – 27th of May)

Confirmed Keynote Speakers Include:

  • Holger Kissel, Vice President Business Alliances, BioNTech SE
  • Laurent Levy, CEO, Nanobiotix Corp.
Confirmed Chairs & Speakers Include:

  • Amir Jafri, Founder & CEO, Immunicom, Inc.
  • Ammar Qadan, Vice President, Global Market Access, illumina
  • Andrew Allen, Co-Founder, President & CEO, Gritstone bio, Inc.
  • Andrew Meadow, General Partner, Health Innovation Capital
  • Angelica Loskog, CEO, Lokon Pharma AB
  • Angus Grant, Chief Business Executive, BeiGene Ltd.
  • Anton Xavier, Director for Startup Life Science Banking, Silicon Valley Bank
  • Bernard Fox, President & CEO, UbiVac
  • Bibhash Mukhopadhyay, Founder & Managing Partner, Sound Bioventures Management AB
  • Biren Amin, CFO, Immuneering Corporation
  • Boris Peaker, Managing Director & Senior Research Analyst, Cowen, Inc.
  • Brad Loncar, CEO, Loncar Investments, LLC
  • Chris Haqq, Head of R&D and CMO, Elicio Therapeutics
  • Christopher Mortko, Director BD, M&A / Oncology, Merck & Co., Inc.
  • Daniel Shelly, Vice President Business Development & Alliances, Prescient Therapeutics Ltd.
  • Daniel Teper, Co-Founder, Chairman & CEO, Cytovia Therapeutics Inc.
  • Debora Barton, CMO, Carisma Therapeutics, Inc.
  • Deepa Talpade, Head of BD&L and Alliance Management for Oncology, Bayer AG
  • Dominique Costantini, CEO, OSE Immunotherapeutics
  • Erica Bozeman, Sr. Scientist (Oncology Scientific Innovation), Johnson & Johnson Innovation LLC
  • Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
  • Gábor Gyülvészi, Sr. Associate, Nextech Invest Ltd.
  • Gregor Fachinger, VP, Head of Oncology & Immuno-Oncology Business Development, Merck KGaA, Darmstadt, Germany
  • Ivo Staijen, Head, Public Equity, HBM Partners AG
  • Jacob Becraft, Co-Founder & CEO, Strand Therapeutics
  • Jami Rubin, CFO, EQRx
  • Jeffrey Bockman, EVP, Head of Oncology Practice, Lumanity
  • Jie Liu, Managing Director, Torreya
  • Johanna Kaufmann, EVP Oncology, Codagenix Inc.
  • John Adamou, Chief Business Officer, CSPC Pharmaceutical Group Limited
  • John Gustofson, Managing Director, AbbVie Ventures
  • Kate Strayer-Benton, Senior Director of Business Development, Dana-Farber Cancer Institute
  • Kaveri Pohlman, Equity Research Analyst, BTIG, LLC
  • Kristen Albright, CEO, Prokarium Ltd.
  • Kuldeep Neote, Entrepreneur In Residence, National Institutes of Health (NIH)
  • Le Zhan, Executive Director, Yunion Healthcare Ventures
  • Lubor Gaal, CFO, Targovax ASA
  • Mai-Britt Zocca, Founder & CEO, IO Biotech ApS
  • Mark Lappe, Founder & CEO, Inhibrx
  • Meredith Fisher, Partner, Mass General Brigham Ventures
  • Michael Rice, VP, Head of Advanced Therapeutics & Rare Diseases, Lumanity
  • Michael Sherman, Executive Vice President & Chief Medical Officer, Point32Health, Inc.
  • Michal Preminger, Head, Johnson & Johnson Innovation, East North America, Johnson & Johnson Innovation LLC
  • Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie, Inc.
  • Patrick Tricoli, CEO of Nanobiotix USA & EVP, Global Head of BD, Nanobiotix Corp.
  • Paul Higham, CEO, Valo Therapeutics Ltd.
  • Paul Lammers, President & CEO, Triumvira Immunologics, Inc.
  • Paul Rennert, President & CSO, Aleta Biotherapeutics
  • Peter Sandor, SVP, PFL Oncology, Astellas Pharma, Inc.
  • Peter Thompson, Partner, OrbiMed Advisors LLC
  • Philippe Lopes-Fernandes, EVP, CBO, Ipsen
  • Portia Ku, Partner (Mergers & Acquisitions), O’Melveny & Myers LLP
  • Roberto De Ponti, Managing Director & General Partner, 3B Future Health Fund
  • Roberto De Ponti, Managing Director & General Partner, 3B Future Health Fund
  • Ryan Schoenfeld, CEO, The Mark Foundation for Cancer Research
  • Steve Dickman, CEO, CBT Advisors
  • Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC
  • Vishal Doshi, Founder & CEO, AUM Biosciences Pte. Ltd.
  • More TBA…